ICER releases draft report on voretigene neparvovec

ICER releases draft report on voretigene neparvovec PharmacoEconomics & Outcomes News 792, p3 - 2 Dec 2017 ICER releases draft report on voretigene neparvovec The US Institute for Clinical and Economic Review (ICER) has released a Draft Evidence Report on the effectiveness and value of voretigene neparvovec for blindness due to biallelic RPE65-mediated inherited retinal disease. This Draft Evidence Report and asssociated Draft Voting Questions will be open for public comment from stakeholders until 13 December 2017. Comments received will be incorporated into the Evidence Report and Revised Voting Questions that ICER expects to post on 11 January 2018. The Evidence Report will then be discussed and voted on at a public meeting of the Midwest CEPAC on 25 January 2018. * Comparative Effectiveness Public Advisory Council Institute for Clinical and Economic Review. Institute for Clinical and Economic Review Releases Draft Evidence Report on Voretigene Neparvovec, Gene Therapy for Blindness Internet Document : 14 Nov 2017. Available from: URL: https://icer- review.org/announcements/voretigene-draft-report/ 803283334 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

ICER releases draft report on voretigene neparvovec

Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/icer-releases-draft-report-on-voretigene-neparvovec-kjJRSfPLry
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
D.O.I.
10.1007/s40274-017-4526-2
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 792, p3 - 2 Dec 2017 ICER releases draft report on voretigene neparvovec The US Institute for Clinical and Economic Review (ICER) has released a Draft Evidence Report on the effectiveness and value of voretigene neparvovec for blindness due to biallelic RPE65-mediated inherited retinal disease. This Draft Evidence Report and asssociated Draft Voting Questions will be open for public comment from stakeholders until 13 December 2017. Comments received will be incorporated into the Evidence Report and Revised Voting Questions that ICER expects to post on 11 January 2018. The Evidence Report will then be discussed and voted on at a public meeting of the Midwest CEPAC on 25 January 2018. * Comparative Effectiveness Public Advisory Council Institute for Clinical and Economic Review. Institute for Clinical and Economic Review Releases Draft Evidence Report on Voretigene Neparvovec, Gene Therapy for Blindness Internet Document : 14 Nov 2017. Available from: URL: https://icer- review.org/announcements/voretigene-draft-report/ 803283334 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792

Journal

PharmacoEconomics & Outcomes NewsSpringer Journals

Published: Dec 2, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from
Google Scholar,
PubMed
Create lists to
organize your research
Export lists, citations
Read DeepDyve articles
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off